Borja Mora‐Peris

Community transmission of monkeypox in the United Kingdom, April to May 2022

Roberto Vivancos, Charlotte Anderson, Paula Blomquist et al. · Eurosurveillance · 2022 · 385 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

José M. Gatell, Lambert Assoumou, Graeme Moyle et al. · Clinical Infectious Diseases · 2018 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy

Borja Mora‐Peris, Victoria Watson, Jaime H. Vera et al. · Journal of Antimicrobial Chemotherapy · 2014 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Ana Gonzalez‐Cordón, Lambert Assoumou, Graeme Moyle et al. · Journal of Antimicrobial Chemotherapy · 2021 · 27 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Medical Eponyms

Borja Mora‐Peris, Xavier Bosch · Archives of Internal Medicine · 2010 · 23 citations

Health Professions, Health Sciences, Clinical Medicine +9